Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development
Open Access
- 4 March 2026
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (3) , e0164325
Abstract
Use of mouse infection models for antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) analysis can assist in dosing regimen design and susceptibility breakpoint development. A major hurdle for clinical translation of in vivo study output is defining the model endpoint linked to clinical success. Validation of the in vivo endpoint requires a clinical data set composed of success or failure linked to minimum inhibitory concentration (MIC), dosing regimen, and if possible human pharmacokinetic measures. The present studies utilized a clinical library of eight Aspergillus fumigatus strains in a mouse pneumonia model to define the endpoint associated with humanized treatment regimens of the triazole, posaconazole. This includes wild-type strains associated with successful treatment and strains with resistance mutations leading to elevated MICs and associated with treatment failure. We found humanized posaconazole exposures resulted in a net stasis or net decrease in organism burden in the animal model compared to the start of therapy for all wild-type strains. However, a net increase in organism burden despite treatment with the humanized regimen was noted for strains with higher MIC values and defined Cyp51 mutations. The ratio of posaconazole free-drug area under the concentration-time curve to the MIC (AUC/MIC) associated with a stasis endpoint in the mouse model was then utilized with in vitro surveillance data and a human posaconazole population pharmacokinetic model to perform simulations and PK/PD target attainment analyses. The results of these analyses demonstrated >90% probability of PK/PD target attainment for A. fumigatus strains with MICs of ≤0.5 mg/L, thus supporting this susceptible breakpoint threshold.Keywords
Funding Information
- U.S. Food and Drug Administration (75F40123C00143)
This publication has 54 references indexed in Scilit:
- Global incidence and mortality of severe fungal diseaseThe Lancet Infectious Diseases, 2024
- Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases PharmacistsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal InfectionThe Journal of Clinical Pharmacology, 2022
- Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agentsBioorganic & Medicinal Chemistry, 2016
- Drug resistance in eukaryotic microorganismsNature Microbiology, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2016
- Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteriaDrug Resistance Updates, 2011
- Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitisDiagnostic Microbiology and Infectious Disease, 2008
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance programMedical Mycology, 2005